HIV-related neurological syndromes reduce health-related quality of life

Canadian Journal of Neurological Sciences

Volumn 32, Issue 2, 2005, Pages 201-204

  Pandya, Rupang ^a   Krentz, Hartmut B ^b   Gill, M John ^a   Power, Christopher ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANADA; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; EDUCATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RISK FACTOR; SENSORY NEUROPATHY; WELLBEING;

EID: 20544455096     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100003978     Document Type: Article

References (11)

1. Sacktor NC, Skolasky RL, Lyles RH, et al. Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J Neurovirol 2000; 6: 84-88.
2. Power C, Gill MJ, Johnson RT. The neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. Can J Neurol Sci 2002; 29: 19-32.
3. Wu AW. Quality-of-life assessment in clinical research: application in diverse populations. Med Care 2000; 38(II): 130-135.
4. Osowiecki DM, Cohen RA, Morrow KM, et al. Neurocognitive and psychological contributions to quality of life in HIV-1-infected women. AIDS 2000; 14: 1327-1332.
5. Benedict RH, Mezhir JJ, Walsh K, et al. Impact of human immunodeficiency virus type-1-associated cognitive dysfunction on activities of daily living and quality of life. Arch Clin Neuropsychol 2000; 15: 535-544.
6. Krentz HB, Auld MC, Gill MJ. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. Can Med Assoc J 2003; 169: 106-110.
7. Janssen R. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force [see comments]. Neurology 1991; 41: 778-785.
8. Bouwman FH, Skolasky RL, Hes D, et al. Variable progression of HIV-associated dementia. Neurology 1998; 50: 1814-1820.
9. Novella JL, Jochum C, Jolly D, et al. Agreement between patients' and proxies' reports of quality of life in Alzheimer's disease. Qual Life Res 2001; 10: 443-452.
10. Saunders DS, Burgoyne RW. Evaluating health-related wellbeing outcomes among outpatient adults with human immunodeficiency virus infection in the HAART era. Int J STD AIDS 2002; 13: 683-690.
11. Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004; 18 (Suppl 1): S75-S78.